Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13
July 06 2022 - 8:10AM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
HAE attacks, building on its deep-seated roots in hereditary
angioedema (HAE), today announced that it will host a virtual
webinar, titled Expert Perspectives on HAE: Unmet Needs and
Therapeutic Options on Wednesday, July 13, 2022, at 10:00 a.m.
ET/16:00 CET.
The virtual event will highlight several topics related to
today’s HAE landscape, including a community member and physician
perspective, as well as current therapeutic needs, followed by a
Q&A session. Presenters for the event are:
- Anthony J. Castaldo, co-founder and President,
HAE International (HAEi), and President, U.S. Hereditary Angioedema
Association (HAEA)
- Marc A. Riedl, M.D., M.S., Professor of
Medicine, Clinical Director of the US Hereditary Angioedema
Association (HAEA) Angioedema Center at the University of
California San Diego (UCSD), and the Training Program Director for
Allergy/Immunology at UCSD
- Berndt Modig, Chief Executive Officer,
Pharvaris
- Peng Lu, M.D., Ph.D., Chief Medical Officer,
Pharvaris
To register for the live webcast, please visit
https://ir.pharvaris.com/news-events/events-presentations in the
News and Events section of the company’s website. Following the
live webcast, an archived replay will be available for at least 30
days after the event.
About PharvarisPharvaris is a clinical-stage
company developing novel, oral bradykinin-B2-receptor antagonists
to treat and prevent HAE attacks, building on its deep-seated roots
in HAE. By directly targeting this clinically proven therapeutic
target with novel small molecules, the Pharvaris team aspires to
offer people with all sub-types of HAE more effective and
convenient alternatives to treat attacks, both on-demand and
prophylactically. The company brings together the best talent in
the industry with deep expertise in rare diseases and HAE. For more
information, visit https://pharvaris.com/
ContactMaryann CiminoDirector of Corporate
Relationsmaryann.cimino@pharvaris.com+1-617-710-7305
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Apr 2023 to Apr 2024